News RWE study shows promise for digital treatment of adult ADHD A study of nearly 20,000 adults with self-reported ADHD diagnoses shows app-based games can improve scores on a battery of cognitive tests.
News Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.
News App to support people with depression launches in GB A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.
News Digital player Hinge Health rises sharply after NYSE debut In a signal of a return to investor appetite for digital health stocks, Hinge Health has raised an impressive $437 million in an IPO.
News Digital therapy for Tourette syndrome backed for NHS use A digital therapy to reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time.
News Despite US turmoil, Hinge Health pushes ahead with IPO Digital health firm Hinge has published a new prospectus for its IPO, shrugging off the weakness in US stock markets caused by Trump's tariffs.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.